Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics has successfully raised approximately $2.735 million through the issuance of 11,891,307 fully paid ordinary shares, following shareholder approval. This capital injection supports ongoing clinical trials of their promising FAK inhibitor, narmafotinib, which has shown efficacy in treating advanced pancreatic cancer. The trials, conducted in Australia and the US, aim to optimize dosing and further establish the drug’s effectiveness in combination with chemotherapy regimens, potentially enhancing Amplia’s position in the oncology market.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company targets fibrotic cancers such as pancreatic and ovarian cancer and addresses chronic diseases like idiopathic pulmonary fibrosis (IPF).
YTD Price Performance: 85.39%
Average Trading Volume: 7,254,682
Technical Sentiment Signal: Buy
Current Market Cap: A$82.69M
Learn more about ATX stock on TipRanks’ Stock Analysis page.